Pomalidomide gets marketing authorisation

Pomalidomide, a new oral blood cancer therapy, has been granted Marketing Authorisation by the European Medicines Agency and is now available in the UK and Ireland. Pomalidomide is for use in combination with dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior therapies including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy. This is based on results from the Phase III MM-003 study, which demonstrated significant advantages for pomalidomide in progression-free survival and overall survival when compared to high dose dexamethasone alone. “Today’s decision